Drug Treatment of Migraine

Department of Clinical Medicine and Prevention, and Center for Clinical Neurosciences, Donau-Universität Krems, Department of Neurology, Landesklinikum Donauregion Tulln Tulln, Austria

Search for more papers by this author

Book Author(s):Nils Erik Gilhus MD, PhD,

Nils Erik Gilhus MD, PhD

Professor

Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway

Search for more papers by this author

Michael P. Barnes MD, FRCP,

Michael P. Barnes MD, FRCP

Professor of Neurological Rehabilitation Medical Director

University of Newcastle, Hunters Moor Neurorehabilitation Ltd, Newcastle upon Tyne, UK

Search for more papers by this author

Michael Brainin MD,

Michael Brainin MD

Professor

Department of Clinical Medicine and Prevention, and Center for Clinical Neurosciences, Donau-Universität Krems, Department of Neurology, Landesklinikum Donauregion Tulln Tulln, Austria

Search for more papers by this author

First published: 06 September 2010

https://doi.org/10.1002/9781444328394.ch10

Summary

This chapter contains sections titled:

Search strategy
Method for reaching consensus
Objectives
Background
Diagnosis
Clinical aspects
Epidemiology
Drug treatment of m igraine attacks
Migraine prophylaxis
Specific situations
References

References

Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004; 24 (Suppl. 1): 1–160.
Google Scholar
Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces–revised recommendations 2004. Eur J Neurol 2004; 11: 577–81.
10.1111/j.1468-1331.2004.00867.x
CAS PubMed Google Scholar
Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The Headaches, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2006; pp. 553–66.
Google Scholar
Evers S, Kropp P, Pothmann R, Heinen F, Ebinger F. Therapie idiopathischer Kopfschmerzen im Kindes-und Jugendalter. Nervenheilkunde 2008; 27: 1127–37.
Web of Science® Google Scholar
Lewis DW. Toward the definition of childhood migraine. Curr Opin Pediatr 2004; 16: 628–36.
10.1097/01.mop.0000143763.17125.03
PubMed Web of Science® Google Scholar
Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, American Academy of Neurology Quality Standards Subcommittee. Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolesdata, cents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63: 2215–24.
10.1212/01.WNL.0000147332.41993.90
CAS PubMed Web of Science® Google Scholar
Maytal J, Young M, Shechter A, Lipton RB. Pediatric migraine and the International Headache Society (IHS) criteria. Neurology 1997; 48: 602–7.
10.1212/WNL.48.3.602
CAS PubMed Web of Science® Google Scholar
Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population–a prevalence study. J Clin Epidemiol 1991; 44: 1147–57.
10.1016/0895-4356(91)90147-2
CAS PubMed Web of Science® Google Scholar
Rasmussen BK. Epidemiology of headache. Cephalalgia 2001; 21: 774–7.
10.1111/j.1468-2982.2001.00248.x
CAS PubMed Web of Science® Google Scholar
Lipton R, Scher A, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: 885–94.
10.1046/j.1526-4610.2001.041007646.x
CAS PubMed Web of Science® Google Scholar
Scher A, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998; 38: 497–506.
10.1046/j.1526-4610.1998.3807497.x
CAS PubMed Web of Science® Google Scholar
Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27: 193–210.
10.1111/j.1468-2982.2007.01288.x
CAS PubMed Web of Science® Google Scholar
Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. Neurology 1994; 44: 1353–4.
10.1212/WNL.44.7.1353
PubMed Google Scholar
Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765–86.
10.1046/j.1468-2982.2000.00117.x
CAS PubMed Web of Science® Google Scholar
Pilgrim AJ. The methods used in clinical trials of sumatriptan in migraine. Headache 1993; 33: 280–93.
Google Scholar
Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 1994; 14: 297–300.
10.1046/j.1468-2982.1994.1404297.x
CAS PubMed Web of Science® Google Scholar
Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self- medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995; 15: 531–5.
10.1046/j.1468-2982.1995.1506531.x
CAS PubMed Web of Science® Google Scholar
Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923–6.
10.1016/S0140-6736(95)91554-0
CAS PubMed Web of Science® Google Scholar
Diener HC, Bussone G, de Liano H, et al., EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24: 947–54.
10.1111/j.1468-2982.2004.00783.x
CAS PubMed Web of Science® Google Scholar
Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 1989; 29: 507–9.
10.1111/j.1526-4610.1989.hed2908507.x
CAS PubMed Web of Science® Google Scholar
Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992; 12: 169–71.
10.1046/j.1468-2982.1992.1203169.x
CAS PubMed Web of Science® Google Scholar
Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute migraine attack with diclofenac sodium: a double-blind study. Headache 1992; 32: 98–100.
10.1111/j.1526-4610.1992.hed3202098.x
CAS PubMed Web of Science® Google Scholar
Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993; 13: 117–23.
10.1046/j.1468-2982.1993.1302117.x
CAS PubMed Web of Science® Google Scholar
The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 19: 232–40.
10.1046/j.1468-2982.1999.019004232.x
PubMed Web of Science® Google Scholar
Göbel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebo-controlled, randomized study. Cephalalgia 2004; 24: 888–93.
10.1111/j.1468-2982.2004.00764.x
CAS PubMed Web of Science® Google Scholar
Tulunay FC, Ergun H, Gulmez SE, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. Funct Neurol 2004; 19: 197–202.
PubMed Web of Science® Google Scholar
Myllyla VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998; 38: 201–7.
10.1046/j.1526-4610.1998.3803201.x
CAS PubMed Web of Science® Google Scholar
Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000; 160: 3486–92.
10.1001/archinte.160.22.3486
CAS PubMed Web of Science® Google Scholar
Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain–three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55: 210–7.
10.1001/archneur.55.2.210
CAS PubMed Web of Science® Google Scholar
Diener H, Pfaffenrath V, Pageler L. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005; 25: 776–87.
10.1111/j.1468-2982.2005.00948.x
CAS PubMed Web of Science® Google Scholar
Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006; 46: 444–53.
10.1111/j.1526-4610.2006.00376.x
CAS PubMed Web of Science® Google Scholar
Limmroth V, May A, Diener HC. Lysine-acetylsalicylic acid in acute migraine attacks. Eur Neurol 1999; 41: 88–93.
10.1159/000008009
CAS PubMed Web of Science® Google Scholar
Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 2002; 42: 862–71.
10.1046/j.1526-4610.2002.02204.x
PubMed Web of Science® Google Scholar
Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004; 52: 50–6.
10.1159/000079544
CAS PubMed Web of Science® Google Scholar
Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007; 254: 705–12.
10.1007/s00415-007-0547-2
CAS PubMed Web of Science® Google Scholar
Kudrow D, Thomas HM, Ruoff G, et al. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. Headache 2005; 45: 1151–62.
10.1111/j.1526-4610.2005.00238.x
CAS PubMed Web of Science® Google Scholar
Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J 2004; 80: 720–3.
10.1136/pgmj.2003.012393
CAS PubMed Web of Science® Google Scholar
Saper J, Dahlöf C, So Y, Tfelt-Hansen P, et al. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache 2006; 46: 264–75.
10.1111/j.1526-4610.2006.00334.x
CAS PubMed Web of Science® Google Scholar
Silberstein S, Tepper S, Brandes J, et al. Randomised placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004; 62: 1552–7.
10.1212/01.WNL.0000123260.61631.C4
CAS PubMed Web of Science® Google Scholar
Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983; 24: 777–85.
10.1007/BF00607087
CAS PubMed Web of Science® Google Scholar
Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984; 4: 85–90.
10.1046/j.1468-2982.1984.0402085.x
CAS PubMed Web of Science® Google Scholar
Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43: 729–33.
10.1046/j.1526-4610.2003.03130.x
PubMed Web of Science® Google Scholar
Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993; 22: 191–5.
10.1016/S0196-0644(05)80201-X
CAS PubMed Web of Science® Google Scholar
Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005; 64: 463–8.
10.1212/01.WNL.0000150904.28131.DD
CAS PubMed Web of Science® Google Scholar
Tfelt-Hansen P, Saxena PR, Dahlöf C, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000; 123: 9–18.
10.1093/brain/123.1.9
PubMed Web of Science® Google Scholar
The Multinational Oral Sumatriptan Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314–22.
10.1159/000116759
PubMed Google Scholar
Diener HC, Reches A, Pascual J, Pascual J, Pitei D, Steiner, TJ, Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Europ Neurol 2002; 47: 99–107.
10.1159/000047960
PubMed Web of Science® Google Scholar
Lainez MJ, Galvan J, Heras J, Vila C. Crossover, double- blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14: 269–75.
10.1111/j.1468-1331.2006.01594.x
CAS PubMed Web of Science® Google Scholar
Christie S, Göbel H, Mateos V, Allen C, Vrijens F, Shivaprakash M, Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/ caffeine in migraine. Eur Neurol 2003; 49: 20–9.
10.1159/000067018
CAS PubMed Web of Science® Google Scholar
Evers S, Gralow I, Bauer B, et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidmiologic study. Clin Neuropharmacol 1999; 22: 201–6.
CAS PubMed Web of Science® Google Scholar
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668–75.
10.1016/S0140-6736(01)06711-3
CAS PubMed Web of Science® Google Scholar
Goadsby PB, Lipton RB, Ferrai MD. Migraine: current understanding and management. N Engl J Med 2002; 346: 257–70.
10.1056/NEJMra010917
Google Scholar
The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992; 32: 177–84.
10.1159/000116818
PubMed Google Scholar
Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002; 47: 88–98.
10.1159/000047959
CAS PubMed Web of Science® Google Scholar
Diamond M, Hettiarachchi J, Hilliard B, Sands G, Nett R. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004; 44: 209–16.
10.1111/j.1526-4610.2004.04049.x
PubMed Web of Science® Google Scholar
Diener HC, for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 1999; 19: 581–8.
10.1046/j.1468-2982.1999.019006581.x
CAS PubMed Web of Science® Google Scholar
Winner P, Ricalde O, Force BL, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180–4.
10.1001/archneur.1996.00550020092020
CAS PubMed Web of Science® Google Scholar
Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002; 42: 28–31.
10.1046/j.1526-4610.2002.02010.x
PubMed Web of Science® Google Scholar
Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55: 19–26.
10.1002/ana.10786
CAS PubMed Web of Science® Google Scholar
Dowson A, Massiou H, Lainez J, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004; 44: 318–22.
10.1111/j.1526-4610.2004.04074.x
CAS PubMed Web of Science® Google Scholar
Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006; 46: 914–24.
10.1111/j.1526-4610.2006.00466.x
CAS PubMed Web of Science® Google Scholar
Goadsby PJ, Zanchin G, Geraud G, et al. Early versus non-early intervention in acute migraine–‘Act when Mild–AwM’. A double-blind placebo-controlled trial of almotriptan. Cephalalgia 2008; 28: 383–91.
10.1111/j.1468-2982.2008.01546.x
CAS PubMed Web of Science® Google Scholar
Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia 2008; 28: 35–40.
10.1111/j.1468-2982.2007.01457.x
PubMed Web of Science® Google Scholar
Linde M, Mellberg A, Dahlöf C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006; 26: 113–21.
10.1111/j.1468-2982.2005.00999.x
CAS PubMed Web of Science® Google Scholar
Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 2007; 27: 1055–60.
10.1111/j.1468-2982.2007.01391.x
CAS PubMed Web of Science® Google Scholar
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48: 1157–68.
10.1111/j.1526-4610.2008.01217.x
PubMed Web of Science® Google Scholar
Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan. Lancet 1999; 353: 378.
10.1016/S0140-6736(05)74950-3
CAS PubMed Web of Science® Google Scholar
Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694–8.
10.1212/WNL.57.9.1694
CAS PubMed Web of Science® Google Scholar
Ferrari MD. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999; 19 (Suppl. 23): 2–8.
10.1177/0333102499019S2302
PubMed Web of Science® Google Scholar
Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330–8.
10.1046/j.1468-2982.1994.1405330.x
CAS PubMed Web of Science® Google Scholar
Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007; 297: 1443–54.
10.1001/jama.297.13.1443
CAS PubMed Web of Science® Google Scholar
Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 2008; 48: 921–30.
10.1111/j.1526-4610.2007.01053.x
CAS PubMed Web of Science® Google Scholar
Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatrip- tan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache 2008; 48: 1286–93.
10.1111/j.1526-4610.2008.01092.x
CAS PubMed Web of Science® Google Scholar
Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache 2005; 45: 874–82.
10.1111/j.1526-4610.2005.05151.x
CAS PubMed Web of Science® Google Scholar
Stark S, Spierings EL, McNeal S, Putnam GP, Bolden- Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40: 513–20.
10.1046/j.1526-4610.2000.00082.x
CAS PubMed Web of Science® Google Scholar
O'Quinn S, Davis RL, Guttermann DL, et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine. Cephalalgia 1999; 19: 223–31.
10.1046/j.1468-2982.1999.019004223.x
CAS PubMed Web of Science® Google Scholar
Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20: 687–95.
10.1111/j.1468-2982.2000.00116.x
CAS PubMed Web of Science® Google Scholar
Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44: 642–51.
10.1111/j.1526-4610.2004.04122.x
CAS PubMed Web of Science® Google Scholar
Hall G, Brown M, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563–8.
10.1212/01.WNL.0000110312.36809.7F
CAS PubMed Web of Science® Google Scholar
Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44: 1587–92.
10.1212/WNL.44.9.1587
CAS PubMed Web of Science® Google Scholar
Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Europ. J Neurol 2004; 11: 671–7.
10.1111/j.1468-1331.2004.00914.x
PubMed Web of Science® Google Scholar
Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks–a review of controlled clinical trials. Cephalalgia 1993; 13: 238–44.
10.1046/j.1468-2982.1993.1304238.x
CAS PubMed Web of Science® Google Scholar
Goadsby PJ. Role of naratriptan in clinical practice. Cephalalgia 1997; 17: 472–3.
10.1046/j.1468-2982.1997.1703153.x
Web of Science® Google Scholar
Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother 2007; 8: 3029–33.
10.1517/14656566.8.17.3029
CAS PubMed Web of Science® Google Scholar
Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes- Hansen S, Färkkilä M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003; 17: 653–67.
10.2165/00023210-200317090-00005
CAS PubMed Web of Science® Google Scholar
Dahlöf C, Cady R, Poole AC. Speed of onset and efficacy of sumatriptan fast-disintegrating/rapid release tablets: results of two replicate randomised, placebo-controlled studies. Headache Care 2004; 1: 277–80.
10.1185/174234304X14845
Google Scholar
The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316–21.
10.1056/NEJM199108013250504
PubMed Web of Science® Google Scholar
Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Neurology 1997; 49: 1225–30.
10.1212/WNL.49.5.1225
CAS PubMed Web of Science® Google Scholar
Tepper SJ, Cochran A, Hobbs S, Woessner M. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998; 52: 31–5.
10.1111/j.1742-1241.1998.tb11555.x
CAS PubMed Web of Science® Google Scholar
Becker WJ, on behalf of the Study Group. A placebo- controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalalgia 1995; 15 (Suppl. 14): 271–6.
Google Scholar
Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. Headache 1998; 38: 737–47.
10.1046/j.1526-4610.1998.3810737.x
CAS PubMed Web of Science® Google Scholar
Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748–55.
10.1046/j.1526-4610.1998.3810748.x
CAS PubMed Web of Science® Google Scholar
Tfelt-Hansen P, Ryan RE. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000; 55 (Suppl. 2): S19–24.
CAS PubMed Web of Science® Google Scholar
Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003; 43: 376–88.
10.1046/j.1526-4610.2003.03073.x
PubMed Web of Science® Google Scholar
Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001; 41: 976–80.
10.1046/j.1526-4610.2001.01191.x
CAS PubMed Web of Science® Google Scholar
Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005; 45: 42–6.
10.1111/j.1526-4610.2005.05009.x
CAS PubMed Web of Science® Google Scholar
Soyka D, Taneri Z, Oestreich W, Schmidt R. Flunarizine i.v. in the acute treatment of the migraine attack. A double-blind placebo-controlled study. Cephalalgia 1988; 8 (Suppl. 8): 35–40.
10.1177/03331024880080S808
PubMed Web of Science® Google Scholar
Silberstein SD, Freitag FG, Rozen TD, et al. Tramadol/ Acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache 2005; 45: 1317–27.
10.1111/j.1526-4610.2005.00264.x
PubMed Web of Science® Google Scholar
Olesen J, Diener HC, Husstedt IW, et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104–10.
10.1056/NEJMoa030505
CAS PubMed Web of Science® Google Scholar
Ho TW, Mannix LK, Fan X, et al. MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304–12.
10.1212/01.WNL.0000286940.29755.61
CAS PubMed Web of Science® Google Scholar
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2009; 372: 2115–23.
10.1016/S0140-6736(08)61626-8
CAS PubMed Web of Science® Google Scholar
Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 1984; 4: 91–6.
10.1046/j.1468-2982.1984.0402091.x
CAS PubMed Web of Science® Google Scholar
Olsson JE, Behring HC, Forssman B, et al. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. Acta Neurol Scand 1984; 70: 160–8.
10.1111/j.1600-0404.1984.tb00815.x
CAS PubMed Web of Science® Google Scholar
Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. Headache 1988; 28: 15–23.
10.1111/j.1365-2524.1988.hed2801015.x
CAS PubMed Web of Science® Google Scholar
Sorensen PS, Larsen BH, Rasmussen MJK, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991; 31: 650–7.
10.1111/j.1526-4610.1991.hed3110650.x
CAS PubMed Web of Science® Google Scholar
Wörz R, Reinhardt-Benmalek B, Grotemeyer KH. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura–a randomized double-blind cross-over multicenter study. Cephalalgia 1991; 11 (Suppl. 11): 152–3.
10.1177/0333102491011S1182
Web of Science® Google Scholar
Diamond S, Medina JL. Double blind study of propranolol for migraine prophylaxis. Headache 1976; 16: 24–7.
10.1111/j.1526-4610.1976.hed1601024.x
CAS PubMed Web of Science® Google Scholar
Tfelt-Hansen P, Standnes B, Kangasniemi P, Hakkarainen H, Olesen J. Timolol vs. propranolol vs. placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984; 69: 1–8.
10.1111/j.1600-0404.1984.tb07772.x
CAS PubMed Web of Science® Google Scholar
Nadelmann JW, Stevens J, Saper JR. Propranolol in the prophylaxis of migraine. Headache 1986; 26: 175–82.
10.1111/j.1526-4610.1986.hed2604175.x
CAS PubMed Web of Science® Google Scholar
Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. Headache 1988; 28: 607–11.
10.1111/j.1526-4610.1988.hed2809607.x
CAS PubMed Web of Science® Google Scholar
Ludin H-P. Flunarizine and propranolol in the treatment of migraine. Headache 1989; 29: 218–23.
10.1111/j.1526-4610.1989.hed22904219.x
Web of Science® Google Scholar
Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31: 333–40.
10.1111/j.1526-4610.1991.hed3105333.x
CAS PubMed Web of Science® Google Scholar
Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992; 19: 340–5.
CAS PubMed Web of Science® Google Scholar
van de Ven LLM, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 1997; 17: 596–9.
10.1046/j.1468-2982.1997.1705596.x
CAS PubMed Web of Science® Google Scholar
Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. A double-blind crossover study. JAMA 1984; 252: 2576–80.
10.1001/jama.1984.03350180030025
CAS PubMed Web of Science® Google Scholar
Johannsson V, Nilsson LR, Widelius T, et al. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache 1987; 27: 372–4.
10.1111/j.1526-4610.1987.hed2707372.x
CAS PubMed Web of Science® Google Scholar
Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine. Headache 1981; 21: 235–9.
10.1111/j.1526-4610.1981.hed2106235.x
PubMed Web of Science® Google Scholar
Diamond S, Schenbaum H. Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine. Headache 1983; 23: 39–42.
10.1111/j.1526-4610.1983.hed2301039.x
CAS PubMed Web of Science® Google Scholar
Amery WK, Caers LI, Aerts TJL. Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache 1985; 25: 249–54.
10.1111/j.1526-4610.1985.hed2505249.x
CAS PubMed Web of Science® Google Scholar
Bono G, Manzoni GC, Martucci N, et al. Flunarizine in common migraine: Italian cooperative trial. II. Long-term follow-up. Cephalalgia 1985; 5 (Suppl. 2): 155–8.
10.1177/03331024850050S229
PubMed Web of Science® Google Scholar
Centonze V, Tesauro P, Magrone D, et al. Efficacy and tolerability of flunarizine in the prophylaxis of migraine. Cephalalgia 1985; 5 (Suppl. 2): 163–8.
10.1177/03331024850050S231
Web of Science® Google Scholar
Nappi G, Sandrini G, Savoini G, Cavallini A, de Rysky C, Micieli G. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine. Drugs 1987; 33 (Suppl. 2): 103–9.
10.2165/00003495-198700332-00019
PubMed Web of Science® Google Scholar
Freitag FG, Diamond S, Diamond M. A placebo controlled trial of flunarizine in migraine prophylaxis. Cephalalgia 1991; 11 (Suppl. 11): 157–8.
10.1177/0333102491011S1185
Web of Science® Google Scholar
Bassi P, Brunati L, Rapuzzi B, Alberti E, Mangoni A. Low dose flunarizine in the prophylaxis of migraine. Headache 1992; 32: 390–2.
10.1111/j.1526-4610.1992.hed3208390.x
CAS PubMed Web of Science® Google Scholar
Diamond S, Freitag FG. A double blind trial of flunarizine in migraine prophylaxis. Headache Quart 1993; 4: 169–72.
Web of Science® Google Scholar
Balkan S, Aktekin B, Önal Z. Efficacy of flunarizine in the prophylactic treatment of migraine. Gazi Med J 1994; 5: 81–4.
Google Scholar
Diener H, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002; 22: 209–21.
10.1046/j.1468-2982.2002.t01-1-00309.x
CAS PubMed Web of Science® Google Scholar
Gerber WD, Schellenberg R, Thom M, et al. Cyclandelate versus propranolol in the prophylaxis of migraine–a double-blind placebo-controlled study. Funct Neurol 1995; 10: 27–35.
CAS PubMed Web of Science® Google Scholar
Diener HC, Föh M, Iaccarino C, et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 1996; 16: 441–7.
10.1046/j.1468-2982.1996.1606441.x
CAS PubMed Web of Science® Google Scholar
Siniatchkin M, Gerber WD, Vein A. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study. Funct Neurol 1998; 13: 47–56.
CAS PubMed Web of Science® Google Scholar
Diener H, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S, on behalf of the Study Group. Cyclandelate in the pro- phylaxis of migraine: a placebo-controlled study. Cephalalgia 2001; 21: 66–70.
10.1046/j.1468-2982.2001.00153.x
CAS PubMed Web of Science® Google Scholar
Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997; 54: 1141–5.
10.1001/archneur.1997.00550210071015
CAS PubMed Web of Science® Google Scholar
Klapper J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103–8.
10.1046/j.1468-2982.1997.1702103.x
CAS PubMed Web of Science® Google Scholar
Silberstein SD, Collins SD, Carlson H. Safety and efficacy of once-daily, extended-release divalproex sodium monotherapy for the prophylaxis of migraine headaches. Cephalalgia 2000; 20: 269.
Google Scholar
Freitag F, Collins S, Carlson H, et al. Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652–9.
10.1212/WNL.58.11.1652
CAS PubMed Web of Science® Google Scholar
Brandes J, Saper J, Diamond M, et al., MIGR -002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965–73.
10.1001/jama.291.8.965
CAS PubMed Web of Science® Google Scholar
Diener H, Tfelt-Hansen P, Dahlöf C, et al. MIGR-003 Study Group. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943–50.
10.1007/s00415-004-0464-6
CAS PubMed Web of Science® Google Scholar
Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 2004; 25: 245–50.
10.1007/s10072-004-0350-0
CAS PubMed Web of Science® Google Scholar
Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490–5.
10.1001/archneur.61.4.490
PubMed Web of Science® Google Scholar
Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814–23.
10.1111/j.1468-2982.2007.01326.x
CAS PubMed Web of Science® Google Scholar
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170–80.
10.1111/j.1526-4610.2006.00684.x
PubMed Web of Science® Google Scholar
Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109–12.
10.1046/j.1468-2982.1997.1702109.x
CAS PubMed Web of Science® Google Scholar
Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura–a pilot study. Cephalalgia 1999; 19: 58–63.
10.1111/j.1468-2982.1999.1901058.x
CAS PubMed Web of Science® Google Scholar
Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119–28.
10.1046/j.1526-4610.2001.111006119.x
CAS PubMed Web of Science® Google Scholar
Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D'Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008; 70: 548–55.
10.1212/01.wnl.0000297551.27191.70
CAS PubMed Web of Science® Google Scholar
Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG. Randomized double blind, placebo-controlled proof-of- concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009; 29: 742–50.
10.1111/j.1468-2982.2008.01804.x
CAS PubMed Google Scholar
Peto R, Gray R, Collins R, Wheatly K, Hennekens C, Jamrozik K. Randomised trial of prophylactic daily aspirin in male British doctors. BMJ 1988; 296: 313–6.
10.1136/bmj.296.6618.313
PubMed Web of Science® Google Scholar
Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264: 1711–3.
10.1001/jama.1990.03450130083031
CAS PubMed Web of Science® Google Scholar
Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985; 42: 582–4.
10.1001/archneur.1985.04060060084014
CAS PubMed Web of Science® Google Scholar
Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985; 35: 1304–10.
10.1212/WNL.35.9.1304
CAS PubMed Web of Science® Google Scholar
Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30: 710–5.
10.1111/j.1526-4610.1990.hed3011710.x
CAS PubMed Web of Science® Google Scholar
Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolfenamic acid: a comparative double-blind crossover study between tolfenamic acid and placebo. Acta Neurol Scand 1982; 66: 105–11.
10.1111/j.1600-0404.1982.tb03134.x
CAS PubMed Web of Science® Google Scholar
Mikkelsen B, Pedersen KK, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand 1986; 73: 423–7.
10.1111/j.1600-0404.1986.tb03299.x
CAS PubMed Web of Science® Google Scholar
Evers S, Mylecharane E. Nonsteroidal antiinflammatory and miscellaneous drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA (eds) The Headaches, 3rd edn. Philadelphia: Lippincott, 2006; pp. 553–66.
Google Scholar
Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychchiatry 1973; 36: 684–90.
10.1136/jnnp.36.4.684
CAS PubMed Web of Science® Google Scholar
Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36: 695–9.
10.1001/archneur.1979.00500470065013
CAS PubMed Web of Science® Google Scholar
Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987; 44: 486–9.
10.1001/archneur.1987.00520170016015
CAS PubMed Web of Science® Google Scholar
Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine: pharmacokinetic and therapeutic effects. Arch Neurol 1993; 50: 825–30.
10.1001/archneur.1993.00540080036010
CAS PubMed Web of Science® Google Scholar
Orholm M, Honoré PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. Acta Neurol Scand 1986; 74: 235–9.
10.1111/j.1600-0404.1986.tb07861.x
CAS PubMed Web of Science® Google Scholar
Zeeberg I, Orholm M, Nielsen JD, Honore PLF, Larsen JJV. Femoxetine in the prophylaxis of migraine–a randomised comparison with placebo. Acta Neurol Scand 1981; 64: 452–9.
10.1111/j.1600-0404.1981.tb04423.x
CAS PubMed Web of Science® Google Scholar
Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992; 32: 101–4.
10.1111/j.1526-4610.1992.hed3202101.x
CAS PubMed Web of Science® Google Scholar
Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18: 283–6.
10.1111/j.1468-2982.1998.1805283.x
CAS PubMed Web of Science® Google Scholar
d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double- blind trial. Headache 1999; 39: 716–9.
10.1046/j.1526-4610.1999.3910716.x
CAS PubMed Google Scholar
Saper JR, Silberstein SD, Lake AE, Winters ME. Double- blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 497–502.
10.1111/j.1526-4610.1994.hed3409497.x
CAS PubMed Web of Science® Google Scholar
Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45: 144–52.
10.1111/j.1526-4610.2005.05029.x
PubMed Web of Science® Google Scholar
Adelman LC, Adelman JU, von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000; 40: 572–80.
10.1046/j.1526-4610.2000.00089.x
CAS PubMed Web of Science® Google Scholar
Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107: 44–8.
10.1016/j.clineuro.2004.03.004
PubMed Web of Science® Google Scholar
Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover trial. BMJ 2001; 322: 19–22.
10.1136/bmj.322.7277.19
CAS PubMed Web of Science® Google Scholar
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized controlled trial. JAMA 2002; 289: 65–9.
10.1001/jama.289.1.65
PubMed Web of Science® Google Scholar
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high- dose riboflavin in migraine prophylaxis–a randomized controlled trial. Neurology 1998; 50: 466–70.
10.1212/WNL.50.2.466
CAS PubMed Web of Science® Google Scholar
Sandor PS, di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomised controlled trial. Neurology 2005; 64: 713–5.
10.1212/01.WNL.0000151975.03598.ED
CAS PubMed Web of Science® Google Scholar
Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine–a double-blind, placebo-controlled study. Cephalalgia 1996; 16: 436–40.
10.1046/j.1468-2982.1996.1606436.x
CAS PubMed Web of Science® Google Scholar
Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257–63.
10.1046/j.1468-2982.1996.1604257.x
CAS PubMed Web of Science® Google Scholar
Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004; 51: 89–97.
10.1159/000076535
CAS PubMed Web of Science® Google Scholar
Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63: 2240–4.
10.1212/01.WNL.0000147290.68260.11
CAS PubMed Web of Science® Google Scholar
Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH, Investigators. The efficacy and safety of Tanacetum parthenium (feverfew) in migraineprophylaxis–a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22: 523–32.
10.1046/j.1468-2982.2002.00396.x
CAS PubMed Web of Science® Google Scholar
Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention–a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25: 1031–41.
10.1111/j.1468-2982.2005.00950.x
CAS PubMed Web of Science® Google Scholar
Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004;(1): CD002286.
CAS PubMed Google Scholar
Silberstein SD. Methysergide. Cephalalgia 1998; 18: 421–35.
10.1111/j.1468-2982.1998.1807421.x
CAS PubMed Web of Science® Google Scholar
Mylecharane EJ. 5-HT2 receptor antagonists and migraine therapy. J Neurol 1991; 238 (Suppl. 1): S45–52.
10.1007/BF01642906
PubMed Web of Science® Google Scholar
Canonico PL, Scapagnini U, Genazzani E, Zanotti A. Dihydroergokryptine (DEK) in the prophylaxis of common migraine: double-blind clinical study vs placebo. Cephalalgia 1989; 9 (Suppl. 10): 446–7.
10.1177/0333102489009S10237
Google Scholar
Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40: 445–50.
10.1046/j.1526-4610.2000.00066.x
CAS PubMed Web of Science® Google Scholar
Brin MF, Swope DM, O'Brian C, Abbasi S, Pogoda JM. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 2000; 20: 421–2.
Google Scholar
Evers S, Vollmer -Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine–a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24: 838–43.
10.1111/j.1468-2982.2004.00754.x
CAS PubMed Web of Science® Google Scholar
Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45: 315–24.
10.1111/j.1526-4610.2005.05068.x
PubMed Web of Science® Google Scholar
Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA -009 Study Group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007; 8: 478–85.
10.1111/j.1526-4637.2006.00168.x
PubMed Web of Science® Google Scholar
Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007; 47: 486–99.
10.1111/j.1526-4610.2006.00624.x
PubMed Web of Science® Google Scholar
Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007; 27: 492–503.
10.1111/j.1468-2982.2007.01315.x
CAS PubMed Web of Science® Google Scholar
Whitmarsh TE, Coleston-Shields DM, Steiner TJ. Double- blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. Cephalalgia 1997; 17: 600–4.
10.1046/j.1468-2982.1997.1705600.x
CAS PubMed Web of Science® Google Scholar
Walach H, Haeusler W, Lowes T, et al. Classical homeopathic treatment of chronic headaches. Cephalalgia 1997; 17: 119–26.
10.1046/j.1468-2982.1997.1702119.x
CAS PubMed Web of Science® Google Scholar
Straumsheim P, Borchgrevink C, Mowinckel P, Kierulf H, Hafslund O. Homeopathic treatment of migraine: a double blind, placebo controlled trial of 68 patients. Br Homeopath J 2000; 89: 4–7.
10.1054/homp.1999.0332
CAS PubMed Google Scholar
Brandes JL, Visser WH, Farmer MV, et al., Protocol 125 study group. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. Headache 2004; 44: 581–6.
10.1111/j.1526-4610.2004.446006.x
PubMed Web of Science® Google Scholar
Vahedi K, Taupin P, Djomby R, et al., DIAMIG investigators. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol 2002; 249: 206–11.
10.1007/PL00007866
CAS PubMed Web of Science® Google Scholar
Goldstein DJ, Offen WW, Klein EG, et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001; 21: 102–6.
10.1046/j.1468-2982.2001.00161.x
CAS PubMed Web of Science® Google Scholar
Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology 2007; 69: 2038–44.
10.1212/01.WNL.0000281105.78936.1d
CAS PubMed Web of Science® Google Scholar
Donaldson D, Sundermann R, Jackson R, Bastani A. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med 2008; 26: 124–30.
10.1016/j.ajem.2007.03.029
PubMed Web of Science® Google Scholar
Innes GD, Macphail I, Dillon EC, Metcalfe C, Gao M. Dexamethasone prevents relapse after emergency department treatment of acute migraine: a randomized clinical trial. CJEM 1999; 1: 26–33.
10.1017/S1481803500006989
CAS PubMed Google Scholar
Rowe BH, Colman I, Edmonds ML, Blitz S, Walker A, Wiens S. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache 2008; 48: 333–40.
10.1111/j.1526-4610.2007.00959.x
PubMed Web of Science® Google Scholar
Baden EY, Hunter CJ. Intravenous dexamethasone to prevent the recurrence of benign headache after discharge from the emergency department: a randomized, double-blind, placebo-controlled clinical trial. CJEM 2006; 8: 393–400.
10.1017/S1481803500014184
PubMed Google Scholar
Bigal ME, Bordini CA, Speciali JG. Intravenous metamizol (Dipyrone) in acute migraine treatment and in episodic tension-type headache–a placebo-controlled study. Cephalalgia 2001; 21: 90–5.
10.1046/j.1468-2982.2001.00143.x
CAS PubMed Web of Science® Google Scholar
Leinisch E, Evers S, Kaempfe N, et al. Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: a double-blind, placebo-controlled parallel group multicenter study. Pain 2005; 117: 396–400.
10.1016/j.pain.2005.07.002
CAS PubMed Web of Science® Google Scholar
Facchinetti F, Fioroni L, Sances G, Romano G, Nappi G, Genazzani AR. Naproxen sodium in the treatment of premenstrual symptoms: a placebo-controlled study. Gynecol Obstet Invest 1989; 28: 205–8.
10.1159/000293579
CAS PubMed Web of Science® Google Scholar
Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985; 25: 320–4.
10.1111/j.1526-4610.1985.hed2506320.x
CAS PubMed Web of Science® Google Scholar
Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30: 705–9.
10.1111/j.1526-4610.1990.hed3011705.x
CAS PubMed Web of Science® Google Scholar
Szekely B, Merryman S, Croft H, Post G. Prophylactic effects of naproxen sodium on perimenstrual headache: a double-blind, placebo-controlled study. Cephalalgia 1989; 9 (Suppl. 10): 452–3.
10.1177/0333102489009S10240
Google Scholar
Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis in menstrually associated migraine: a randomised, double-blind, placebo-controlled study. Headache 2001; 41: 248–56.
10.1046/j.1526-4610.2001.111006248.x
CAS PubMed Web of Science® Google Scholar
Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63: 261–9.
10.1212/01.WNL.0000134620.30129.D6
CAS PubMed Web of Science® Google Scholar
Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007; 47: 1037–49.
10.1111/j.1526-4610.2007.00855.x
PubMed Web of Science® Google Scholar
De Lignieres B, Mauvais-Javis P, Mas JML, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. BMJ 1986; 293: 1540.
10.1136/bmj.293.6561.1540
CAS PubMed Web of Science® Google Scholar
Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double blind trial of percutaneous oestradiol. Gynecol Endocrinol 1988; 2: 113–20.
10.3109/09513598809023619
CAS PubMed Web of Science® Google Scholar
Smits MG, van den Meer YG, Pfeil JPJM, Rijnierse JJMM, Vos AJM. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 1994; 34: 103–6.
10.1111/j.1526-4610.1994.hed3402103.x
CAS PubMed Web of Science® Google Scholar
Pradalier A, Vincent D, Beaulieu PH, Baudesson G, Launay J-M. Correlation between estradiol plasma level and therapeutic effect on menstrual migraine. Proc 10th Migraine Trust Symp 1994; 129–32.
Google Scholar
MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006; 67: 2159–63.
10.1212/01.wnl.0000249114.52802.55
CAS PubMed Web of Science® Google Scholar
O'Quinn S, Ephross SA, Williams V, Davis RL, Gutterman DL, Fox AW. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 1999; 263: 7–12.
10.1007/s004040050252
CAS PubMed Web of Science® Google Scholar
Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20–4.
10.1046/j.1526-4610.2000.00003.x
CAS PubMed Web of Science® Google Scholar
Källen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41: 351–6.
10.1046/j.1526-4610.2001.111006351.x
CAS PubMed Web of Science® Google Scholar
Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings EL. Evidence -based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42: 8–15.
10.1046/j.1526-4610.2002.02007.x
PubMed Web of Science® Google Scholar
Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003; 17: 1–7.
10.2165/00023210-200317010-00001
CAS PubMed Web of Science® Google Scholar
Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42: 543–9.
10.1345/aph.1K176
CAS PubMed Web of Science® Google Scholar
Goadsby PJ, Goldberg J, Silberstein SD. The pregnant migraineur: what can be done? Br Med J 2008; 336: 1502–4.
10.1136/bmj.39559.675891.AD
PubMed Web of Science® Google Scholar
Evers S, May A, Fritsche G, et al. Akuttherapie und Prophylaxe der Migräne. Leitlinie der Deutschen Migräne-und Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. Nervenheilkunde 2008; 27: 933–49.
Web of Science® Google Scholar
Überall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology 1999; 52: 1507–10.
10.1212/WNL.52.7.1507
PubMed Web of Science® Google Scholar
Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000; 106: 989–97.
10.1542/peds.106.5.989
CAS PubMed Web of Science® Google Scholar
Ahonen K, Hämäläinen M, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004; 62: 883–7.
10.1212/01.WNL.0000115105.05966.A7
CAS PubMed Web of Science® Google Scholar
Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? Neurology 1997; 48: 1100–3.
10.1212/WNL.48.4.1100
CAS PubMed Web of Science® Google Scholar
Evers S. Drug treatment of migraine in children. A comparative review. Paediatr Drugs 1999; 1: 7–18.
10.2165/00128072-199901010-00002
CAS PubMed Google Scholar
Winner P, Lewis D, Visser H, Jiang K, Ahrens S, Evans JK, Rizatriptan Adolescent Study Group. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002; 42: 49–55.
10.1046/j.1526-4610.2002.02013.x
PubMed Web of Science® Google Scholar
Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219–25.
10.1212/WNL.49.5.1219
CAS PubMed Web of Science® Google Scholar
Tepper SJ, Donnan GA, Dowson AJ, et al. A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin 1999; 15: 254–71.
10.1185/03007999909116496
CAS PubMed Web of Science® Google Scholar
Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006; 67: 497–9.
10.1212/01.wnl.0000231138.18629.d5
CAS PubMed Web of Science® Google Scholar
Lewis DW, Winner P, Hershey AD, Wasiewski WW, Adolescent Migraine Steering Committee. Efficacy of zolmi- triptan nasal spray in adolescent migraine. Pediatrics 2007; 120: 390–6.
10.1542/peds.2007-0085
PubMed Web of Science® Google Scholar
Ahonen K, Hämäläinen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006; 67: 1135–40.
10.1212/01.wnl.0000238179.79888.44
CAS PubMed Web of Science® Google Scholar
Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45: 1304–12.
10.1111/j.1526-4610.2005.00262.x
CAS PubMed Web of Science® Google Scholar
Winner P, Gendolla A, Stayer C, et al. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache 2006; 46: 1503–10.
10.1111/j.1526-4610.2006.00610.x
CAS PubMed Web of Science® Google Scholar

European Handbook of Neurological Management, Volume 1, Second Edition